| 名稱 | Zoligratinib |
| 描述 | Zoligratinib (CH5183284) is a selective and orally available FGFR inhibitor, which is for FGFR1(IC50=9.3 nM), FGFR2(IC50=7.6 nM), FGFR3(IC50=290), and FGFR4(IC50=22 nM), respectively. |
| 細(xì)胞實(shí)驗(yàn) | The cell lines are added to the wells of 96-well plates containing 0.076 to 10,000 nM CH5183284/Debio 1347 and incubated at 37°C. After 4 days of incubation, Cell Counting Kit-8 solution is added and, after incubation for several more hours, absorbance at 450 nm is measured with the iMark Microplate-Reader. The antiproliferative activity is calculated using the formula (1 ? T/C) × 100 (%), where T and C represent absorbance at 450 nm of the cells treated with drugs (T) and that of untreated control cells (C). The IC50 values are calculated using Microsoft Excel 2007.(Only for Reference) |
| 激酶實(shí)驗(yàn) | Protein kinase assay: The inhibitory activity of CH5183284/Debio 1347 against FGFR1 is evaluated using a radiometric filter assay by measuring the incorporation of 33Pi with a microplate scintillation counter. The phosphorylation activities of LCK, EGFR, KIT, MET, SRC, BRK, FGFR2, Flt3, LTK, INSR, YES, ABL, EPHA2, ZAP70, Fyn, IGF1R, KDR, and PDGFR on substrate peptides are determined by homogeneous time-resolved fluorescence assay with LANCE Eu-W1024 labeled anti-phosphotyrosine PT66 antibody according to standard methods. Time-resolved fluorescence is measured with an EnVision HTS microplate reader. The activities of Aurora A, Akt1/PKBα, PKA, Cdk1/cyclin B, Cdk2/cyclin A, PKCα, PKCβ1 and PKCβ2 on substrate peptides are determined by IMAP FP Screening Express Progressive Binding System. Fluorescence polarization is measured with an EnVision HTS microplate reader. |
| 體外活性 | 在DMS114（FGFR1擴(kuò)增）、SNU-16（FGFR2擴(kuò)增）和KMS11細(xì)胞系中，CH5183284（100至300 nM）阻止了FGFR1、FGFR2和FGFR3的自磷酸化。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| 溶解度 | Ethanol : 1 mg/mL (2.81 mM), Heating is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (28.06 mM), Solution.
DMSO : 250 mg/mL (701.5 mM), Sonication is recommended.
10% DMSO+90% Saline : < 10 mg/mL (28.06 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
|
| 關(guān)鍵字 | Zoligratinib | Inhibitor | inhibit | Fibroblast growth factor receptor | FGFR4 | FGFR3 | FGFR2 | FGFR1 | FGFR | FF-284 | FF 284 | Debio-1347 | Debio1347 | CH-5183284 | CH 5183284 |
| 相關(guān)產(chǎn)品 | Amlexanox | Lenvatinib | Formononetin | Lenvatinib mesylate | Ferulic Acid | Regorafenib | Pazopanib | Nintedanib | Erdafitinib | Ferulic acid sodium | Regorafenib monohydrate | Nintedanib esylate |
| 相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 細(xì)胞因子抑制劑庫 | 激酶抑制劑庫 | NO PAINS 化合物庫 | 膜蛋白靶向化合物庫 | 藥物功能重定位化合物庫 | 酪氨酸激酶分子庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |